News - Mergers & Acquisitions, Neurological

Filter

Popular Filters

1 to 25 of 57 results

Biotie passes up on option to acquire Neurelis

Biotie passes up on option to acquire Neurelis

14-07-2014

Finland-based biotech firm Biotie Therapies said on Friday that it has decided not to exercise its exclusive…

Acute repetitive seizuresBiotechnologyBiotie TherapiesDiazepamFinlandHepatologyMergers & AcquisitionsNeurelisNeurologicalNRL-1Pediatric and adult epilepsyPharmaceuticalResearchtozadenant

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Kyowa Hakko to acquire Archimedes for £230 million

Kyowa Hakko to acquire Archimedes for £230 million

11-07-2014

Through its Scotland-based subsidiary ProStrakan Group, Japanese drugmaker Kyowa Hakko Kirin has entered…

ArchimedesArchimedes PharmaBusiness FinanceDriverHealth Medical PharmaKyowa Hakko KirinMergers & AcquisitionsNeurologicalNovo A/SOncologyPharmaceuticalPharmaceutical industryProStrakanUK

Lundbeck to complete Chelsea Thera acquisition today

Lundbeck to complete Chelsea Thera acquisition today

23-06-2014

Danish CNS specialist Lundbeck says that it has completed the tender offer to buy all of the outstanding…

Chelsea TherapeuticsLundbeckMergers & AcquisitionsNeurologicalNortheraPharmaceutical

Roche partners in new company for MS research

Roche partners in new company for MS research

23-06-2014

Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

03-06-2014

Israel generics giant Teva Pharmaceutical Industries has entered into a definitive agreement to acquire…

AmgenBiotechnologyLabrys BiologicsLBR-101Mergers & AcquisitionsNeurologicalTeva Pharmaceutical Industries

Cipla invests $1.5 million for 14.6% stake in USA’s Chase Pharma

14-05-2014

Indian drugmaker Cipla has said it will acquire a 14.6% stake in US-based Chase Pharmaceuticals for $1.5…

Chase PharmaceuticalsCiplaCPC 201Mergers & AcquisitionsNeurologicalPharmaceutical

Lundbeck in deal to acquire Chelsea Therapeutics

Lundbeck in deal to acquire Chelsea Therapeutics

08-05-2014

Danish CNS specialist Lundbeck revealed today that it has entered into a definitive agreement to acquire…

BiotechnologyChelsea TherapeuticsLundbeckMergers & AcquisitionsNeurologicalNorthera

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

30-04-2014

US pharma major Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused…

BiotechnologyBristol-Myers SquibbiPierianIPN007Mergers & AcquisitionsNeurological

Perrigo transfers ELND005 assets; buys OTC products

01-03-2014

Drugmaker Perrigo has entered into a series of agreements with existing collaboration partner, Transition…

ELND005Mergers & AcquisitionsNeurologicalPerrigoPharmaceuticalResearchTransition Therapeutics

NuPathe accepts Teva’s higher counter bid, rejecting Endo offer

21-01-2014

Israel-based Teva Pharmaceutical Industries seems set to bag ownership of US drugmaker NuPathe), which…

Endo Health SolutionsMergers & AcquisitionsNeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

NuPathe rockets on news of takeover by Endo Health

NuPathe rockets on news of takeover by Endo Health

16-12-2013

In a third take-over deal announced this year, USA-based specialty health care company Endo Health Solutions…

Endo Health SolutionsMergers & AcquisitionsNeurologicalNuPathePharmaceuticalZecuity

Torrent to acquire Indian branded formulations from Elder

13-12-2013

Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded…

Asia-PacificElder PharmaceuticalsIndiaMergers & AcquisitionsNeurologicalPharmaceuticalTorrent PharmaceuticalsWomen's Health

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Sorrento Therapeutics gets clinical-stage chronic pain drug, along with Sherrington acquisition

16-10-2013

Sorrento Therapeutics has acquired Sherrington Pharmaceuticals. Financial terms of the deal were not…

CynviloqMergers & AcquisitionsNeurologicalPharmaceuticalresiniferatoxinSherrington PharmaceuticalsSorrento Therapeutics

Sangamo BioSciences to buy Ceregene

28-08-2013

In its first takeover bid since 2001, US drugmaker Sangamo BioSciences (Nasdaq: SGMO) has signed a definitive…

BiotechnologyCERE-110CeregeneMergers & AcquisitionsNeurologicalOphthalmicsSangamo BioSciences

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Ipsen makes acquisition and signs R&D deal with Harvard

15-07-2013

French drugmaker Ipsen (Euronext: IPN) has acquired UK life sciences company Syntaxin for an upfront…

EuropeIpsenMergers & AcquisitionsNeurologicalPharmaceuticalSyntaxin

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate

04-06-2013

Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?

29-04-2013

US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Phytopharm views options, including merger, as Cogane fails

27-03-2013

UK-based Phytopharm (LSE: PYM: London Stock Exchange), ahead of its annual general meeting today (March…

CoganeMergers & AcquisitionsNeurologicalPharmaceuticalPhytopharmResearch

Elan sells its Tysabri rights to Biogen; posts 2012 financials

07-02-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

1 to 25 of 57 results

Back to top